101 results
Page 3 of 6
8-K
EX-99.1
y6h5eumvhr8zqcf8wr
10 Dec 21
Regulation FD Disclosure
8:16am
8-K
EX-99.1
g5kwlo2mjnwasw11r
3 Nov 21
Arvinas Reports Third Quarter 2021 Financial Results and Provides Corporate Update
4:01pm
8-K
EX-99.1
s88ti 3xuu039i8qo07l
28 Sep 21
Regulation FD Disclosure
7:30am
424B5
3zvngqtv1wx8s8gne
6 Aug 21
Prospectus supplement for primary offering
4:34pm
8-K
EX-1.1
zyn66n7nycvmdh90l
6 Aug 21
Entry into a Material Definitive Agreement
4:09pm
8-K
EX-99.1
q08r217fys 6w7secz
22 Jul 21
Arvinas and Pfizer Announce Global Collaboration to Develop and Commercialize PROTACĀ® Protein
7:30am
8-K
EX-10.1
ex14ot2g ew5texi
22 Jul 21
Arvinas and Pfizer Announce Global Collaboration to Develop and Commercialize PROTACĀ® Protein
7:30am
8-K
EX-99.1
dsb9cqf gc5b
4 May 21
Arvinas Reports First Quarter 2021 Financial Results and Provides Corporate Update
4:02pm
8-K
EX-99.1
5z7nkpa6
1 Mar 21
Arvinas Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Corporate Update
4:03pm
8-K
EX-1.1
egkacqn1wkoh1ijp9f
18 Dec 20
Arvinas, Inc. Announces Pricing of $400 Million Public Offering of Common Stock
6:30am
424B5
5w9c1flgd21tqudi1
16 Dec 20
Prospectus supplement for primary offering
4:01pm
424B5
t5p39d4bhy03gr
14 Dec 20
Prospectus supplement for primary offering
4:48pm
8-K
EX-99.1
poi66
14 Dec 20
Regulation FD Disclosure
7:30am
8-K
EX-99.2
d9uzb3z8
14 Dec 20
Regulation FD Disclosure
7:30am